Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Pharmacological improvements may help KRN633 beat diseases related to pathological angiogenesis
February 27th, 2006
Pharmacological improvements may help KRN633 beat diseases related to pathological angiogenesis. According to recent research from Japan, "KRN633 is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. However, it is poorly water-soluble; consequently, relatively high doses are required to achieve substantial in vivo tumor growth suppression after oral administration." "We subjected KRN633 to the solid dispersion technique to improve its solubility, absorption, and antitumor efficacy after oral administration. This technique transformed the drug into an amorphous state and dramatically improved its dissolution...
Source: Pharma Business Week (2006-02-27)
|
